Search research articles
Contact Us
Filters
Showing results (761-770 of 888) with videos related to
Page
of 89
Sort By:
Scientific Reports
|
November 3, 2025
IGF-1 regulates cancer cell immune evasion in prostate cancer
Ashwin M Nandakumar, Alessandro Barberis, Jinseon Kim, et al.
European Journal of Pharmacology
|
May 20, 1997
In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists
N M Rupniak, F D Tattersall, A R Williams, et al.
Nature Immunology
|
November 14, 2018
Metabolic reprogramming of natural killer cells in obesity limits antitumor responses
Xavier Michelet, Lydia Dyck, Andrew Hogan, et al.
NAR Cancer
|
August 4, 2020
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma
Chris W D Armstrong, Jonathan A Coulter, Chee Wee Ong, et al.
Psychological Medicine
|
July 13, 2016
Psychological processes underlying the association between childhood trauma and psychosis in daily life: an experience sampling study
U Reininghaus, C Gayer-Anderson, L Valmaggia, et al.
Postgraduate Medical Journal
|
February 25, 2023
A Women in Medicine Trainees' Council: a model for women trainee professional development
A Sofia C Warner, Nneka N Ufere, Naomi J Patel, et al.
Oncogene
|
September 27, 2016
Cell cycle-coupled expansion of AR activity promotes cancer progression
C McNair, A Urbanucci, C E S Comstock, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 14, 2009
Disubstituted pyrimidines as Lck inhibitors
Julianne A Hunt, Richard T Beresis, Joung L Goulet, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity
Jeffrey J Hale, Richard J Budhu, Sander G Mills, et al.
Journal of Medicinal Chemistry
|
November 7, 1998
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist
J J Hale, S G Mills, M MacCoss, et al.
Page
of 89
Search research articles
Search
Showing results (761-770 of 888) with videos related to
Sort By:
Page
of 89
Scientific Reports
|
November 3, 2025
IGF-1 regulates cancer cell immune evasion in prostate cancer
Ashwin M Nandakumar, Alessandro Barberis, Jinseon Kim, et al.
European Journal of Pharmacology
|
May 20, 1997
In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists
N M Rupniak, F D Tattersall, A R Williams, et al.
Nature Immunology
|
November 14, 2018
Metabolic reprogramming of natural killer cells in obesity limits antitumor responses
Xavier Michelet, Lydia Dyck, Andrew Hogan, et al.
NAR Cancer
|
August 4, 2020
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma
Chris W D Armstrong, Jonathan A Coulter, Chee Wee Ong, et al.
Psychological Medicine
|
July 13, 2016
Psychological processes underlying the association between childhood trauma and psychosis in daily life: an experience sampling study
U Reininghaus, C Gayer-Anderson, L Valmaggia, et al.
Postgraduate Medical Journal
|
February 25, 2023
A Women in Medicine Trainees' Council: a model for women trainee professional development
A Sofia C Warner, Nneka N Ufere, Naomi J Patel, et al.
Oncogene
|
September 27, 2016
Cell cycle-coupled expansion of AR activity promotes cancer progression
C McNair, A Urbanucci, C E S Comstock, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 14, 2009
Disubstituted pyrimidines as Lck inhibitors
Julianne A Hunt, Richard T Beresis, Joung L Goulet, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity
Jeffrey J Hale, Richard J Budhu, Sander G Mills, et al.
Journal of Medicinal Chemistry
|
November 7, 1998
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist
J J Hale, S G Mills, M MacCoss, et al.
Page
of 89